Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges
Backgroundrespiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infections worldwide, imposing a substantial disease burden on infants, older adults, and immunocompromised individuals. Despite its prevalence, therapeutic options have historically been limited, with no...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2026-02-01
|
| Серія: | Frontiers in Microbiology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fmicb.2026.1745808/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|